
In 2021, Boston Scientific added 20.3 percent to its endoscopy business, and sold endoscopes for USD 2.14bn, compared to 2020’s result of USD 1.78bn, the company reports in its full-year 2021 financial report.
Accounting for currency fluctuations, that equates to a 18.9-percent growth in the company’s endoscopy division, and Boston Scientific has a revenue of USD 11.88bn and a growth in the entire group of 18.7 percent after currency fluctuations.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app